Evid Based Nurs 8:78 doi:10.1136/ebn.8.3.78
  • Treatment

Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations

Budesonide (BUD) plus formoterol (FORM) for both maintenance and symptom relief (BUDFORM for all) v fixed dosing using BUDFORM or a 4 fold higher dose of BUD, both with a short acting β2 agonist (SABA) in asthma*

Outcome at 1 year Comparisons Event rates RRR (95% CI) NNT (CI)
*Abbreviations defined in glossary; RRR, NNT, and CI calculated from Cox proportional hazard ratios in article.
⩾1 severe asthma exacerbation BUDFORM for all v BUDFORM plus SABA 16% v 27% 41% (30 to 52) 10 (8 to 13)
BUDFORM for all v BUD plus SABA 16% v 28% 43% (31 to 53) 9 (7 to 12)

This Article

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBN.
View free sample issue >>

EBN Journal Chat

The EBN Journal Chat offers readers the opportunity to participate in discussion about research articles and commentaries from Evidence Based Nursing (EBN).

How to participate >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article